GlyphAllo is named as an intervention in 2 current clinical trials in our USA, Germany, Poland and Czechia registers. 1 is recruiting patients now. All registered phases are Phase 2. The lead sponsor is Seaport Therapeutics. The most-studied condition is Major Depressive Disorder (MDD).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
NCT07065240 · ClinicalTrials.gov ↗ · Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
|
Phase 2 | Recruiting | Seaport Therapeutics | USA, Germany, Poland, Czechia |
|
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
NCT07161700 · ClinicalTrials.gov ↗ · Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
|
Phase 2 | By invitation | Seaport Therapeutics | USA, Germany, Poland, Czechia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Seaport Therapeutics | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 1 |
| Clinical trials in Germany | 2 | 1 |
| Clinical trials in Poland | 2 | 1 |
| Clinical trials in Czechia | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our USA, Germany, Poland and Czechia registers name GlyphAllo (also registered as SPT-300) as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in USA, 1 with sites in Germany, 1 with sites in Poland and 1 with sites in Czechia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Seaport Therapeutics. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how GlyphAllo works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how GlyphAllo works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists GlyphAllo (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.